Wall Street analyst estimates for Cencora, Inc. (COR): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment.
Consensus price target
$357.75 (+8 % vs price $330.84)
between $330.00 and $400.00 · 8 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $337B | $337B – $337B | $17.89 | 7 |
| 2027E | $352B | $350B – $355B | $19.73 | 6 |
Fiscal year ending in September · figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 33 |
| Hold | 12 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 46 |
| Avg rating (−2 sell to +2 buy) | 0.70 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $4.58 | ||
| 2026-08-05 | $4.48 | $4.35 | +3.0% |
| 2026-05-06 | $4.75 | $4.82 | -1.5% |
| 2026-02-04 | $4.08 | $4.05 | +0.7% |
| 2025-11-05 | $3.84 | $3.79 | +1.3% |
| 2025-08-06 | $4.00 | $3.85 | +3.9% |
| 2025-05-07 | $4.42 | $4.11 | +7.5% |
| 2025-02-05 | $3.73 | $3.50 | +6.6% |
Valuation Ratios
| P/E Ratio | 24.58 |
| Price / Book | 20.94 |
| EV / EBITDA | 13.99 |
| Dividend Yield | 0.73% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146.85B | $153.14B | $167.94B | $179.59B | $189.89B | $213.99B | $238.59B | $262.17B | $293.96B | $321.33B |
| Cost of Revenue | $143.08B | $149.00B | $163.83B | $175.06B | $185.10B | $207.72B | $230.99B | $254.42B | $285.26B | $311.19B |
| Gross Profit | $3.77B | $4.15B | $4.11B | $4.53B | $4.79B | $6.27B | $7.60B | $7.76B | $8.70B | $10.14B |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $2.09B | $2.13B | $2.46B | $2.66B | $2.77B | $3.59B | $4.85B | $5.31B | $5.66B | $6.49B |
| Operating Expenses | $2.09B | $2.13B | $2.46B | $2.66B | $2.77B | $3.59B | $4.85B | $5.31B | $5.66B | $6.49B |
| Operating Income | $1.68B | $2.02B | $1.65B | $1.87B | $2.02B | $2.68B | $2.75B | $2.45B | $3.04B | $3.65B |
| EBITDA | $1.92B | $1.49B | $1.87B | $1.65B | -$4.73B | $2.91B | $3.11B | $3.41B | $3.36B | $3.74B |
| Interest Expense | $144.3M | $149.0M | $189.6M | $195.5M | $158.5M | $182.5M | $232.0M | $275.6M | $248.7M | $419.8M |
| Pre-tax Income | $1.39B | $917.9M | $1.18B | $967.1M | -$5.29B | $2.22B | $2.18B | $2.16B | $2.00B | $2.26B |
| Income Tax | -$37.0M | $553.4M | -$438.5M | $113.0M | -$1.89B | $677.3M | $516.5M | $428.3M | $484.7M | $690.5M |
| Net Income | $1.43B | $414.5M | $1.66B | $855.4M | -$3.40B | $1.54B | $1.70B | $1.75B | $1.51B | $1.55B |
| EPS | $6.73 | $1.67 | $7.61 | $4.07 | $-16.60 | $7.48 | $8.15 | $8.62 | $7.60 | $8.02 |
| EPS (Diluted) | $6.32 | $1.64 | $7.53 | $4.04 | $-16.60 | $7.39 | $8.04 | $8.53 | $7.53 | $7.96 |
| Shares Outstanding (Diluted) | 226.0 M | 221.6 M | 220.3 M | 211.8 M | 204.8 M | 208.5 M | 211.2 M | 204.6 M | 200.3 M | 195.2 M |
Price
| Price | $330.84 (closing price, October 30, 2026) |
| Market Cap | $63.1B |
| Exchange | NYSE |
| Country | US |
Related companies: HSIC · MCK · CAH · 0JZU.L · 0HF3.L · 0HTG.L · 0L3C.L · 0ROG.L
Explore sector: Healthcare · Medical - Distribution
More sections of COR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks